Sourcing · Regulatory · continued

Prescription requirements and telehealth models posts 91–98

Sourcing › Regulatory FDA compounding research use only MHRA

This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.

c.rasmussenTL2 Moderator26 Dec 2025#91

Why this category is maintained as documentation, not as recommendations: the goal is factual accuracy and sourcing, not endorsement of any specific regulatory position.

3 likes 7mo

j.nascimentoTL2 Moderator26 Dec 2025#92

Research-use-only status is a legal classification, not a safety classification. It means the compound is sold for laboratory use and not for human consumption. The label does not establish whether the molecule is safe, efficacious, or toxic.

10 likes 7mo

c.bakkerTL2 Moderator26 Dec 2025#93

n.achebe, post #59: post #58 answers the question as asked. The question underneath it is different. Primary documents matter: regulatory positions are published in official documents. Reading the regulatory agency's website directly is more reliable than reading a forum summary of it. Go to post

This follows post #90 rather than contradicting it.

For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.

31 likes in reply to #59 7mo

c.ramosTL2 Moderator27 Dec 2025#94

Compounding and pharmacy rules: some jurisdictions allow a pharmacy to compound a drug that is not on the market under specific conditions. The conditions are strict and vary by jurisdiction. Generalising from one country's rules to another's is unreliable.

0 likes 7mo

t.demirTL2 Moderator27 Dec 2025#95

Primary documents matter: regulatory positions are published in official documents. Reading the regulatory agency's website directly is more reliable than reading a forum summary of it.

6 likes 7mo

e.silvaTL2 Moderator28 Dec 2025 · edited#96

f.sjoberg, post #29: On post #25 — agreed on the reasoning, with one qualification. Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive. Go to post

Regulatory positions change: a compound's status today might differ from its status a year from now. Citing a regulatory position is worth doing only with a date attached.

16 likes in reply to #29 7mo

an.adeyemiTL2 Moderator28 Dec 2025#97

t.verhoeven, post #51: For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use. Go to post

Picking up post #94: that is the part I would want checked first.

Import restrictions vary by compound and by jurisdiction: what is a controlled substance in one place is legal to purchase in another. What you can import for personal use depends on your country's rules, not on where it is sold.

0 likes in reply to #51 7mo

e.lokkenTL2 Moderator29 Dec 2025#98

Coming back to post #96, because the follow-up matters more than the original answer.

Labelling and intended use: a compound sold as "research-use-only" does not change its pharmacology if ingested. It changes the legal status of the sale. The labelling tells you the intended use, not the actual use people make of it.

1 like 7mo

This topic was referenced in

What a regulator's shortage notice actually authorisesSourcing › Regulatory · 12 replies
Second pass at: Import rules for personal quantities, by jurisdiction, datedSourcing › Regulatory · 2 replies

Suggested topics

Topic	Participants	Replies	Views	Activity
Follow-up: How compounding permissions changed when supply normalised Sourcing › Regulatory MHRA personal import research use only How compounding permissions changed when supply normalised I have a specific reason for asking rather than idle curiosity, and the context is below. Structured report rather than an opinion, following the…	+72	77	1.5k	1d
Reading a regulatory notice rather than an article about it — what changed since Sourcing › Regulatory research use only MHRA FDA personal import Reading a regulatory notice rather than an article about it — what changed since — setting out what I have, and where I think it stops being reliable. A logistics question, since the answers here are usually…	+28	32	640	13mo
Pharmaceutical compounding rules, summarised from primary sources — a second dataset Sourcing › Regulatory MHRA research use only compounding Posting this under the heading it deserves: Pharmaceutical compounding rules, summarised from primary sources — a second dataset Everything below is what sits behind that. A logistics question, since the…	+50	56	780	8mo
Enforcement priorities versus written rules Sourcing › Regulatory FDA personal import MHRA Enforcement priorities versus written rules — setting out what I have, and where I think it stops being reliable. I would like to talk about documentation quality as a signal, separately from product quality.…		2	62k	15mo
Second pass at: Import rules for personal quantities, by jurisdiction, dated Sourcing › Regulatory research use only personal import FDA MHRA Second pass at: Import rules for personal quantities, by jurisdiction, dated Writing it up because I had to work it out twice and would rather nobody else did. A logistics question, since the answers here are…		2	5k	11mo

Related topics — sharing the tags FDA, compounding, research use only

Topic	Participants	Replies	Views	Activity
Import rules for personal quantities, by jurisdiction, dated Sourcing › Regulatory compounding MHRA FDA personal import On the subject in the title: Import rules for personal quantities, by jurisdiction, dated Working notes rather than a conclusion. Structured report rather than an opinion, following the format the maintainers…		3	60k	12mo
Coming back to: When "no data" is the complete and final answer Compounds › Other compounds research use only needs a source custom synthesis When "no data" is the complete and final answer I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a claim I…	+77	82	12k	11mo
Manufacturer assistance programmes and their eligibility rules Access › Pricing formulary data table compounding On the subject in the title: Manufacturer assistance programmes and their eligibility rules Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category…	+37	42	32k	11d
Managing an unplanned gap in supply Access › Shortages shortage formulary FDA compounding Managing an unplanned gap in supply — setting out what I have, and where I think it stops being reliable. A coverage question with the paperwork detail included, since that is what determines the answer.…	+105	110	5.1k	3mo
Cost per milligram, computed honestly across formats — the long version Access › Pricing cost per milligram compounding formulary data table Cost per milligram, computed honestly across formats — the long version Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail…	+111	124	24k	14mo